Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics Q2 2025 Earnings Report

Artiva Biotherapeutics logo
$2.76 -0.12 (-4.01%)
As of 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Artiva Biotherapeutics EPS Results

Actual EPS
-$0.87
Consensus EPS
-$0.84
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Artiva Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artiva Biotherapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Artiva Biotherapeutics' Q2 2025 earnings is scheduled for Thursday, August 7, 2025

Artiva Biotherapeutics Earnings Headlines

Artiva (ARTV) Q2 Loss Widens 19.7%
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Artiva Biotherapeutics Rings the Closing Bell
See More Artiva Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email.

About Artiva Biotherapeutics

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

View Artiva Biotherapeutics Profile

More Earnings Resources from MarketBeat